Half Moon Bay, CA, United States of America

Lawrence M DeYoung

This inventor holds 2 USPTO granted patents. Top assignee: Syntex (u.s.a.) Inc.. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lawrence M DeYoung. Retrieved from https://idiyas.com/inventor/lawrence-m-deyoung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 49(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
2 patents (USPTO):Explore Patents

Certainly! Here is the article about inventor Lawrence M DeYoung:

Title: Unveiling the Innovations of Lawrence M DeYoung in the Field of Transglutaminase Inhibitors

Introduction: Lawrence M DeYoung, a talented inventor hailing from Half Moon Bay, CA (US), has made significant contributions to the realm of transglutaminase inhibitors. With a focus on the treatment of acne, DeYoung's inventive spirit shines through in his creations.

Latest Patents:

1. Transglutaminase inhibitors: DeYoung's groundbreaking patent introduces 3,5 substituted, 4,5-dihydroisoxazoles as transglutaminase inhibitors, showcasing their efficacy in combating epidermal transglutaminase and treating acne.

2. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors: Another pivotal patent by DeYoung, highlighting the potency of certain compounds in inhibiting transglutaminase, particularly targeting epidermal transglutaminase for acne treatment.

Career Highlights: Within his tenure at Syntex (USA) Inc., Lawrence M DeYoung has demonstrated a keen aptitude for innovation, pushing the boundaries of pharmaceutical research. His dedication to improving treatments for skin conditions like acne has positioned him as a notable figure in the field.

Collaborations: DeYoung's creative endeavors have been bolstered by collaborations with esteemed colleagues such as Arlindo L Castelhano and Alexander Krantz. Together, they have synergized their expertise to advance the development of transglutaminase inhibitors.

Conclusion: In conclusion, Lawrence M DeYoung's pioneering work in the realm of transglutaminase inhibitors underscores his commitment to innovation and healthcare advancements. Through his patents and collaborations, he continues to carve a path towards more effective treatments for dermatological conditions, leaving a lasting impact on the field.

If you need more information or assistance, feel free to ask!

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…